According to the Zhitong Finance App, Insili Intelligence (03696.HK) announced that ISM6331, its self-developed AI-based potential best-in-class innovative pan-TEAD inhibitor, has obtained Fast Track Qualification (FTD) from the US Food and Drug Administration (FDA) to treat adult patients with unresectable malignant pleural mesothelioma who have previously received anti-PD-1 antibody treatment (whether combined with or without anti-CTLA-4 antibody therapy) and platinum-containing chemotherapy.

According to the Zhitong Finance App, Insili Intelligence (03696.HK) announced that ISM6331, its self-developed AI-based potential best-in-class innovative pan-TEAD inhibitor, has obtained Fast Track Qualification (FTD) from the US Food and Drug Administration (FDA) to treat adult patients with unresectable malignant pleural mesothelioma who have previously received anti-PD-1 antibody treatment (whether combined with or without anti-CTLA-4 antibody therapy) and platinum-containing chemotherapy.